Reaction Intermediate Analogues for Enolase
Overview
Authors
Affiliations
A number of compounds that appear to be analogues of the aci form of the normal carbanion intermediate are good inhibitors of yeast enolase. These include (3-hydroxy-2-nitropropyl)phosphonate (I), the ionized (pK = 8.1) nitronate form of which in the presence of 5 mM Mg2+ has a Ki of 6 nM, (nitroethyl)phosphonate (III) (pK = 8.5; Ki of the nitronate in the presence of 5 mM Mg2+ = 1 microM), phosphonoacetohydroxamate (IV) (pK = 10.2; Ki with saturating Mg2+ for the ionized form = 15 pM), and (phosphonoethyl)nitrolate (VII) (Ki at 1 mM Mg2+ = 14 nM). The oxime of phosphonopyruvate (VI) has a pH-independent Ki of 75 microM. I, IV, VI, and VII are slow binding inhibitors. All of these compounds are trigonal at the position analogous to C-2 of 2-phosphonoglycerate and contain a phosphono group, but a negatively charged metal ligand at the position isosteric with the hydroxyl attached to C-3 of 2-phosphoglycerate (as in IV) appears to contribute more to binding than a nitro group isosteric with the carboxyl of 2-phosphoglycerate (I and III). These data support the carbanion mechanism for enolase and suggest that the 3-hydroxyl of 2-phosphoglycerate is directly coordinated to Mg2+ prior to being eliminated to give phosphoenolpyruvate.
Yan V, Pham C, Ballato E, Yang K, Arthur K, Khadka S J Med Chem. 2022; 65(20):13813-13832.
PMID: 36251833 PMC: 9620261. DOI: 10.1021/acs.jmedchem.2c01039.
Khan M, Ahmed I, Din I, Noureldeen A, Darwish H, Khan M PLoS One. 2022; 17(5):e0264453.
PMID: 35511817 PMC: 9070951. DOI: 10.1371/journal.pone.0264453.
Targeting cancer metabolism in the era of precision oncology.
Stine Z, Schug Z, Salvino J, Dang C Nat Rev Drug Discov. 2021; 21(2):141-162.
PMID: 34862480 PMC: 8641543. DOI: 10.1038/s41573-021-00339-6.
Ramirez Rios S, Torres A, Diemer H, Collin-Faure V, Cianferani S, Lafanechere L PLoS One. 2021; 16(5):e0252450.
PMID: 34048472 PMC: 8162644. DOI: 10.1371/journal.pone.0252450.
An enolase inhibitor for the targeted treatment of ENO1-deleted cancers.
Lin Y, Satani N, Hammoudi N, Yan V, Barekatain Y, Khadka S Nat Metab. 2020; 2(12):1413-1426.
PMID: 33230295 PMC: 7744354. DOI: 10.1038/s42255-020-00313-3.